How a Renegotiated NAFTA Could Keep Drug Prices High for Patients

This fact sheet provides key takeaways and resources for lawmakers and was shared at the Capitol Hill briefing on September 14, 2018.

Key Takeaways:

  • U.S.–Mexico agreement on 10 years keeps brand drug prices high for longer
  • A renegotiated NAFTA should lower – not increase – drug prices for patients
  • Higher drug prices abroad ≠ lower drug prices in the U.S.
  • Imposes additional barrier to emerging biosimilars market in U.S.
  • Growing export markets for generics and biosimilars is in U.S. national interest


Download Fact Sheet

Watch Briefing


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.